<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Decoy Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/decoy-therapeutics-inc</link>
<description>Latest news and press releases for Decoy Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/decoy-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7497d51cc36e475333709.webp</url>
<title>Decoy Therapeutics Inc.</title>
<link>https://6ix.com/company/decoy-therapeutics-inc</link>
</image>
<item>
<title>Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-to-present-at-two-peptide-therapeutics-conferences-in-boston</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-to-present-at-two-peptide-therapeutics-conferences-in-boston</guid>
<pubDate>Mon, 27 Apr 2026 12:45:00 GMT</pubDate>
<description>Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral mechanisms using its proprietary peptide conjugate platform, IMP3ACT™, today announced that members of its executive leadership will present across two leading peptide therapeutics conferences in Boston the week of April 27, 2026.</description>
</item>
<item>
<title>Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-builds-momentum-with-accelerating-execution-entering-a-highly-catalytic-phase-with-a-clearly-defined-path-to-clinical-development-of-its-antiviral-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-builds-momentum-with-accelerating-execution-entering-a-highly-catalytic-phase-with-a-clearly-defined-path-to-clinical-development-of-its-antiviral-pipeline</guid>
<pubDate>Thu, 09 Apr 2026 12:36:00 GMT</pubDate>
<description>Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today highlighted a series of recent strategic, operational and scientific achievements that underscore accelerating momentum and a clear trajectory toward becoming a clinical-stage company. The Company also outlined upcoming milestones that are expected to drive shareholder value.</description>
</item>
<item>
<title>Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-to-participate-in-virtual-investor-closing-bell-event-highlighting-business-outlook-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-to-participate-in-virtual-investor-closing-bell-event-highlighting-business-outlook-for-2026</guid>
<pubDate>Mon, 06 Apr 2026 13:15:00 GMT</pubDate>
<description>Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, announced that Rick Pierce, Chief Executive Officer of Decoy, will participate in a Virtual Investor Closing Bell event on Thursday, April 9, 2026, at 4:00 PM ET.</description>
</item>
<item>
<title>Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-2</guid>
<pubDate>Thu, 02 Apr 2026 13:00:00 GMT</pubDate>
<description>Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq Stock Market LLC that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement and is now in compliance with all other applicable continued listing requirements of The Nasdaq Capital Market.</description>
</item>
<item>
<title>Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-enters-strategic-partnership-with-quantori-to-deploy-google-cloud-native-integrated-ai-driven-peptide-design-and-molecular-simulation-platform</guid>
<pubDate>Wed, 11 Mar 2026 12:30:00 GMT</pubDate>
<description>Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically inc</description>
</item>
<item>
<title>Decoy Therapeutics Announces 1-for-12 Reverse Stock Split</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-announces-1-for-12-reverse-stock-split-16</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-announces-1-for-12-reverse-stock-split-16</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the</description>
</item>
<item>
<title>Decoy Therapeutics Joins Webull Corporate Connect Service Platform</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-joins-webull-corporate-connect-service-platform-1</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-joins-webull-corporate-connect-service-platform-1</guid>
<pubDate>Wed, 11 Feb 2026 14:00:00 GMT</pubDate>
<description>Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform.</description>
</item>
<item>
<title>Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial</guid>
<pubDate>Thu, 05 Feb 2026 14:15:00 GMT</pubDate>
<description>Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026.</description>
</item>
<item>
<title>Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recently-announced-global-access-commitment-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recently-announced-global-access-commitment-agreement</guid>
<pubDate>Wed, 04 Feb 2026 14:02:00 GMT</pubDate>
<description>Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the Company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation.</description>
</item>
<item>
<title>Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform</title>
<link>https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-reaches-global-access-commitment-agreement-to-focus-on-development-of-a-globally-accessible-scalable-peptide-conjugate-manufacturing-platform</link>
<guid isPermaLink="true">https://6ix.com/company/decoy-therapeutics-inc/news/decoy-therapeutics-reaches-global-access-commitment-agreement-to-focus-on-development-of-a-globally-accessible-scalable-peptide-conjugate-manufacturing-platform</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from</description>
</item>
</channel>
</rss>